Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

amgen k. k. - blinatumomab(genetical recombination) - lyophilized injection

Israel - English - Ministry of Health

amgen europe b.v. - romiplostim - powder for solution for injection - romiplostim 250 mcg/vial - romiplostim - romiplostim - adults:nplate is indicated for the treatment of primary immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).paediatrics:nplate is indicated for the treatment of chronic primary immune thrombocytopenia (itp) in paediatric patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Israel - English - Ministry of Health

amgen europe b.v. - denosumab - solution for injection - denosumab 120 mg / 1.7 ml - denosumab - denosumab - prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with multiple myeloma and in adults with bone metastases from solid tumours.treatment of adult and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

Israel - English - Ministry of Health

amgen europe b.v. - panitumumab - concentrate for solution for infusion - panitumumab 20 mg / 1 ml - panitumumab - in combination with chemotherapy for the treatment of unresectable, advanced or recurrent colorectal cancer (mcrc) with wild-type ras.monotherapy for the treatment of patients with metastatic colorectal carcinoma with wild-type ras after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Israel - English - Ministry of Health

amgen europe b.v. - romiplostim - powder for solution for injection - romiplostim 500 mcg/vial - romiplostim - nplate is indicated for chronic immune (idiopathic) thrombocytopenic purpura (itp) patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Israel - English - Ministry of Health

amgen europe b.v. - etelcalcetide as hydrochloride - solution for injection - etelcalcetide as hydrochloride 5 mg / 1 ml - etelcalcetide - parsabiv is indicated for the treatment of secondary hyperparathyroidism (shpt) in adult patients with chronic kidney disease (ckd) on hemodialysis therapy.

Israel - English - Ministry of Health

amgen europe b.v. - carfilzomib - powder for solution for injection - carfilzomib 2 mg/ml - carfilzomib - kyprolis is indicated: o for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy in combination with: • lenalidomide and dexamethasone; or • dexamethasone; or • daratumumab (i.v or s.c) and dexamethasone.o in combination with isatuximab and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.o as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. approval is based on response rate. clinical benefit, such as improvement in survival or symptoms, has not been verified.

Israel - English - Ministry of Health

amgen europe b.v. - carfilzomib - powder for solution for injection - carfilzomib 2 mg/ml - carfilzomib - kyprolis is indicated: o for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy in combination with: • lenalidomide and dexamethasone; or • dexamethasone; or • daratumumab (i.v or s.c) and dexamethasone.o in combination with isatuximab and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.o as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. approval is based on response rate. clinical benefit, such as improvement in survival or symptoms, has not been verified.

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 10 mcg / 0.4 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 100 mcg / 0.5 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age